Stoke Therapeutics (STOK) Change in Accured Expenses (2018 - 2026)

Stoke Therapeutics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$15.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 431.55% year-over-year to -$15.7 million; the TTM figure through Mar 2026 stood at $829000.0 (down 91.5% YoY), while the FY2025 annual figure was $21.3 million, up 589.41% from the prior year.
• Change in Accured Expenses was -$15.7 million for Q1 2026 at Stoke Therapeutics, down from $8.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.9 million in Q4 2025 to a low of -$15.7 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $112941.2 across 5 years, with a median of $351000.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses tumbled 677.39% in 2023, then surged 751.67% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $199000.0 in 2022, then sank by 677.39% to -$1.1 million in 2023, then soared by 289.64% to $2.2 million in 2024, then jumped by 308.54% to $8.9 million in 2025, then sank by 276.58% to -$15.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$15.7 million (Q1 2026), $8.9 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.